US pediatrician group recommends against routine use of drug for autism

The American Academy of Pediatrics (AAP) has advised against the routine use of leucovorin, a generic form of vitamin B9 originally developed by GSK, for children with autism, citing a lack of evidence regarding its benefits and risks. This guidance follows a surge in parental demand after U.S. health officials mentioned the drug, which is primarily used in chemotherapy and is under FDA review for a rare genetic condition causing autism-like symptoms, though the FDA has also noted limited data concerning its direct use in autism.

Analysis

The American Academy of Pediatrics (AAP) has issued guidance advising against the routine use of leucovorin for children with autism, citing a critical lack of evidence regarding its benefits and risks. This advisory directly counters a surge in parental demand, which was fueled by a prior White House press conference that highlighted the generic drug.

While the FDA is processing approval for leucovorin in cerebral folate deficiency, a rare genetic condition causing autism-like symptoms, it has acknowledged limited data for its direct use in autism. Dr. Kristin Sohl, an autism expert involved in the AAP guidance, underscored significant unknowns regarding the drug's safety, efficacy, and appropriate dosing for autistic children.

This development highlights increasing regulatory scrutiny on off-label drug prescriptions, particularly for vulnerable populations and conditions lacking robust clinical trial data. Although GSK originally developed leucovorin, its generic status and the advisory's focus on off-label use suggest a limited direct financial impact on the company, as indicated by the low market impact score of 0.1.

Key Decisions for Investors

• Monitor regulatory trends concerning off-label drug prescriptions, particularly in pediatric and neurological conditions, as increased scrutiny may impact pharmaceutical companies.
• Evaluate pharmaceutical and biotech firms developing treatments for autism based on the robustness of their clinical trial data and regulatory pathways, prioritizing those with strong evidence.
• Consider the implications for generic drug manufacturers and the broader healthcare sector where off-label use of established drugs is common, as similar advisories could emerge.